Loading quotes...
Forecast
The analysts' average price target is €108.68 (-2.35%). The median is €109.72 (-1.42%).
| Buy |
9 |
| Hold |
18 |
| Sell |
5 |
News Go to news feed
Aflac prioritizes human empathy over AI for sensitive customer interactions
Aflac says AI and automation should handle routine transactions, but human agents are essential for sensitive health-related calls where empathy matters. Keith Farley, Aflac’s chief customer officer, emphasizes hiring for authentic empathy rather than trying to train it, and leaders should "walk the process" to experience customer journeys firsthand. The company advocates balancing efficiency gains from AI with easy access to humans for reassurance and complex issues. » More on forbes.com
Aflac viewed as steady but unspectacular by Jim Cramer
Jim Cramer characterized Aflac as "not great, not bad," reflecting a low-risk, low-growth profile. In Q2 Aflac reported net earnings of $825 million versus $599 million a year earlier, while total revenues fell to $4.1 billion amid foreign-exchange headwinds and weaker yen-driven results in Japan. Management returned $1.3 billion in capital through $983 million of buybacks and $309 million of dividends, supporting a long history of dividend increases. Revenue and adjusted earnings were pressured by currency translation, leaving upside limited but downside contained. » More on finance.yahoo.com
Aflac uses high‑yield environment in Japan to reposition portfolio and drive growth
At the KBW Insurance Conference 2026, Aflac presented a strategy of capital discipline, selective growth and operational improvements. The company repositioned roughly 5% of its Japan portfolio, boosting net investment income and reducing valuation risks, while savings and life products and the new reinsurance offering Aflac Re are providing growth. In the US, Aflac is selectively expanding group and direct business as well as dental and vision benefits, but expects significant scale effects only in 2–3 years. AI is expected to deliver efficiency gains, but is not seen as the primary lever to lower expense ratios; the capital position remains comfortably above target levels. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 3.58bn | 0.03% |
| Gross profit | 1.95bn | 94.77% |
| Net profit | 722.87m | 42.24% |
| EBITDA | 1.13bn | 61.45% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €55.18bn |
Number of shares | 501.34m |
52-week high/low | €115.69 - €93.71 |
Dividend yield | 1.87% |
Dividends TTM | €2.07 |
Beta | 0.56 |
P/E ratio | 13.29 |
PEG ratio | 0.12 |
P/B ratio | 2.06 |
P/S ratio | 3.43 |
Company profile
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates through two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care income support, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan. The Aflac U.S. segment provides cancer, accident, short-term disability, critical illness, hospital indemnity, dental, vision, long-term care and disability, and term and whole life insurance products in the United States. It sells its products through sales associates, brokers, independent corporate agencies, individual agencies, and affiliated corporate agencies. The company was founded in 1955 and is based in Columbus, Georgia.
| Name | AFLAC |
| CEO | Daniel Paul Amos |
| Headquarters | Columbus,
ga USA |
| Website | |
| Sector | Financials |
| Industry | Insurance |
| IPO | 17/03/1980 |
| Employees | 12,716 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | AFL |
London Stock Exchange | 0H68.L |
XETRA | AFL.DE |
Frankfurt | AFL.F |
Düsseldorf | AFL.DU |
Hamburg | AFL.HM |
London | 0H68.L |
SIX | AFL.SW |
München | AFL.MU |
Wien | AFL.VI |